PD-Rx Launches New Trade Division - TriMarc Laboratories

PD-Rx Launches New Trade Division - TriMarc Laboratories 


OKLAHOMA CITY, May 19  /PRNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc.
(OTC Pink Sheets: PDRX), a publicly held corporation, today announced a new
trade division, TriMarc Laboratories.  The new division will be marketing
branded pharmaceutical products to the healthcare industry.

"The TriMarc Laboratories Division was formed with growth opportunities in
mind," stated Dr. Robert D. Holsey, President and CEO of PD-Rx Pharmaceuticals.
 The new division will be offering exclusively licensed and patented
pharmaceutical products to an ever-growing healthcare market.  With several new
products in research and development, TriMarc's current negotiations will lead
to rapid growth through co-marketing programs with larger pharmaceutical
marketing firms.

ABOUT THE COMPANY

PD-Rx offers pharmaceutical and management strategies to the healthcare
industry.  Our management strategies focus on new products, solid business
partners, and the specialized segment of the pharmaceutical industry.  As a
licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of
medications and specialized services.  Our goal is to develop a matrix of cost
containment tools and products that we can merge into any healthcare network to
enhance patient care and improve managed care organizations bottom line. We
provide proprietary products and prepackaged medications that are viewed by
patient, insurance payers, and healthcare providers as a progressive and
responsive practice.

This press release contains "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995.  Such forward-looking
statements involve known and unknown risks and uncertainties or other factors,
which may cause actual results, performance or achievements expressed or
implied by such forward-looking statements to vary from those forecast or
implied in this release.  Factors that might cause such a difference include,
without limitation, decline in demand for the company's products or services,
and the effect of general economic conditions and factors affecting the
industry. 

DATASOURCE: PD-Rx Pharmaceuticals, Inc.



CONTACT:  Jack L. McCall, EVP & COO of PD-Rx Pharmaceuticals, Inc.,

[phone], or  

Copyright